A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naive Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology
Latest Information Update: 22 Apr 2026
At a glance
- Drugs Berzosertib (Primary) ; Carboplatin; Gemcitabine; Pembrolizumab
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 09 Apr 2026 Planned End Date changed from 8 May 2026 to 18 Mar 2027.
- 24 Mar 2026 Planned End Date changed from 12 Apr 2025 to 8 May 2026.
- 13 Apr 2024 Planned End Date changed from 15 Aug 2024 to 12 Apr 2025.